RT @TracyBethHoeg: Oh boy. @CDCgov released data on the new bivalent booster & it doesn't look good at 2-3 months. They used test negative…
RT @TracyBethHoeg: Oh boy. @CDCgov released data on the new bivalent booster & it doesn't look good at 2-3 months. They used test negative…
RT @TracyBethHoeg: Oh boy. @CDCgov released data on the new bivalent booster & it doesn't look good at 2-3 months. They used test negative…
RT @TracyBethHoeg: Oh boy. @CDCgov released data on the new bivalent booster & it doesn't look good at 2-3 months. They used test negative…
RT @MartyMakary: CDC just released its bivalent vax study-says effectiveness "should be interpreted with caution because unvaccinated perso…
RT @SukunaBikona7: 従来型2回以上接種と比較した従来型2回以上接種+2価ワクチン1回接種の相対的な発症予防効果(最終の従来型接種から2-3ヶ月→8ヶ月以上)は18-49歳30%→56%、50-64歳31%→48%、65歳以上28%→43%。 https://t…
RT @SukunaBikona7: 従来型2回以上接種と比較した従来型2回以上接種+2価ワクチン1回接種の相対的な発症予防効果(最終の従来型接種から2-3ヶ月→8ヶ月以上)は18-49歳30%→56%、50-64歳31%→48%、65歳以上28%→43%。 https://t…
RT @SukunaBikona7: 従来型2回以上接種と比較した従来型2回以上接種+2価ワクチン1回接種の相対的な発症予防効果(最終の従来型接種から2-3ヶ月→8ヶ月以上)は18-49歳30%→56%、50-64歳31%→48%、65歳以上28%→43%。 https://t…
Oh boy. @CDCgov released data on the new bivalent booster & it doesn't look good at 2-3 months. They used test negative design so very likely *over*estimates effectiveness if biv boosted people have lower threshold to test & VE still only 20-30% i
RT @SukunaBikona7: 従来型2回以上接種と比較した従来型2回以上接種+2価ワクチン1回接種の相対的な発症予防効果(最終の従来型接種から2-3ヶ月→8ヶ月以上)は18-49歳30%→56%、50-64歳31%→48%、65歳以上28%→43%。 https://t…
RT @SukunaBikona7: 従来型2回以上接種と比較した従来型2回以上接種+2価ワクチン1回接種の相対的な発症予防効果(最終の従来型接種から2-3ヶ月→8ヶ月以上)は18-49歳30%→56%、50-64歳31%→48%、65歳以上28%→43%。 https://t…
RT @SukunaBikona7: 従来型2回以上接種と比較した従来型2回以上接種+2価ワクチン1回接種の相対的な発症予防効果(最終の従来型接種から2-3ヶ月→8ヶ月以上)は18-49歳30%→56%、50-64歳31%→48%、65歳以上28%→43%。 https://t…
RT @SukunaBikona7: 従来型2回以上接種と比較した従来型2回以上接種+2価ワクチン1回接種の相対的な発症予防効果(最終の従来型接種から2-3ヶ月→8ヶ月以上)は18-49歳30%→56%、50-64歳31%→48%、65歳以上28%→43%。 https://t…
RT @SukunaBikona7: 従来型2回以上接種と比較した従来型2回以上接種+2価ワクチン1回接種の相対的な発症予防効果(最終の従来型接種から2-3ヶ月→8ヶ月以上)は18-49歳30%→56%、50-64歳31%→48%、65歳以上28%→43%。 https://t…
RT @SukunaBikona7: 従来型2回以上接種と比較した従来型2回以上接種+2価ワクチン1回接種の相対的な発症予防効果(最終の従来型接種から2-3ヶ月→8ヶ月以上)は18-49歳30%→56%、50-64歳31%→48%、65歳以上28%→43%。 https://t…
RT @MartyMakary: CDC just released its bivalent vax study-says effectiveness "should be interpreted with caution because unvaccinated perso…
RT @MartyMakary: CDC just released its bivalent vax study-says effectiveness "should be interpreted with caution because unvaccinated perso…
RT @SukunaBikona7: 従来型2回以上接種と比較した従来型2回以上接種+2価ワクチン1回接種の相対的な発症予防効果(最終の従来型接種から2-3ヶ月→8ヶ月以上)は18-49歳30%→56%、50-64歳31%→48%、65歳以上28%→43%。 https://t…
RT @SukunaBikona7: 従来型2回以上接種と比較した従来型2回以上接種+2価ワクチン1回接種の相対的な発症予防効果(最終の従来型接種から2-3ヶ月→8ヶ月以上)は18-49歳30%→56%、50-64歳31%→48%、65歳以上28%→43%。 https://t…
RT @SukunaBikona7: 従来型2回以上接種と比較した従来型2回以上接種+2価ワクチン1回接種の相対的な発症予防効果(最終の従来型接種から2-3ヶ月→8ヶ月以上)は18-49歳30%→56%、50-64歳31%→48%、65歳以上28%→43%。 https://t…
RT @SukunaBikona7: 従来型2回以上接種と比較した従来型2回以上接種+2価ワクチン1回接種の相対的な発症予防効果(最終の従来型接種から2-3ヶ月→8ヶ月以上)は18-49歳30%→56%、50-64歳31%→48%、65歳以上28%→43%。 https://t…
RT @SukunaBikona7: 従来型2回以上接種と比較した従来型2回以上接種+2価ワクチン1回接種の相対的な発症予防効果(最終の従来型接種から2-3ヶ月→8ヶ月以上)は18-49歳30%→56%、50-64歳31%→48%、65歳以上28%→43%。 https://t…
RT @SukunaBikona7: 従来型2回以上接種と比較した従来型2回以上接種+2価ワクチン1回接種の相対的な発症予防効果(最終の従来型接種から2-3ヶ月→8ヶ月以上)は18-49歳30%→56%、50-64歳31%→48%、65歳以上28%→43%。 https://t…
RT @SukunaBikona7: 従来型2回以上接種と比較した従来型2回以上接種+2価ワクチン1回接種の相対的な発症予防効果(最終の従来型接種から2-3ヶ月→8ヶ月以上)は18-49歳30%→56%、50-64歳31%→48%、65歳以上28%→43%。 https://t…
RT @MartyMakary: CDC just released its bivalent vax study-says effectiveness "should be interpreted with caution because unvaccinated perso…
@AviDascalu https://t.co/nFMLzQH0XI Of course, MMWR released today only modest effectiveness of bivalent booster.
RT @AAPSonline: Receiving more doses does not seem to add much to vaccine efficacy as far as prevention of infection. Not to mention there…
RT @SukunaBikona7: 従来型2回以上接種と比較した従来型2回以上接種+2価ワクチン1回接種の相対的な発症予防効果(最終の従来型接種から2-3ヶ月→8ヶ月以上)は18-49歳30%→56%、50-64歳31%→48%、65歳以上28%→43%。 https://t…
RT @SukunaBikona7: 従来型2回以上接種と比較した従来型2回以上接種+2価ワクチン1回接種の相対的な発症予防効果(最終の従来型接種から2-3ヶ月→8ヶ月以上)は18-49歳30%→56%、50-64歳31%→48%、65歳以上28%→43%。 https://t…
@D28EquityNow This report just came out today, not sure how helpful it is Re: young boys but it does talk a little about effectiveness https://t.co/OK2it2MZwq
RT @SukunaBikona7: 従来型2回以上接種と比較した従来型2回以上接種+2価ワクチン1回接種の相対的な発症予防効果(最終の従来型接種から2-3ヶ月→8ヶ月以上)は18-49歳30%→56%、50-64歳31%→48%、65歳以上28%→43%。 https://t…
RT @MartyMakary: CDC just released its bivalent vax study-says effectiveness "should be interpreted with caution because unvaccinated perso…
RT @SukunaBikona7: 従来型2回以上接種と比較した従来型2回以上接種+2価ワクチン1回接種の相対的な発症予防効果(最終の従来型接種から2-3ヶ月→8ヶ月以上)は18-49歳30%→56%、50-64歳31%→48%、65歳以上28%→43%。 https://t…
RT @MartyMakary: CDC just released its bivalent vax study-says effectiveness "should be interpreted with caution because unvaccinated perso…
RT @MartyMakary: CDC just released its bivalent vax study-says effectiveness "should be interpreted with caution because unvaccinated perso…
RT @SukunaBikona7: 従来型2回以上接種と比較した従来型2回以上接種+2価ワクチン1回接種の相対的な発症予防効果(最終の従来型接種から2-3ヶ月→8ヶ月以上)は18-49歳30%→56%、50-64歳31%→48%、65歳以上28%→43%。 https://t…
RT @SukunaBikona7: 従来型2回以上接種と比較した従来型2回以上接種+2価ワクチン1回接種の相対的な発症予防効果(最終の従来型接種から2-3ヶ月→8ヶ月以上)は18-49歳30%→56%、50-64歳31%→48%、65歳以上28%→43%。 https://t…
RT @SukunaBikona7: 従来型2回以上接種と比較した従来型2回以上接種+2価ワクチン1回接種の相対的な発症予防効果(最終の従来型接種から2-3ヶ月→8ヶ月以上)は18-49歳30%→56%、50-64歳31%→48%、65歳以上28%→43%。 https://t…
RT @SukunaBikona7: 従来型2回以上接種と比較した従来型2回以上接種+2価ワクチン1回接種の相対的な発症予防効果(最終の従来型接種から2-3ヶ月→8ヶ月以上)は18-49歳30%→56%、50-64歳31%→48%、65歳以上28%→43%。 https://t…
RT @SukunaBikona7: 従来型2回以上接種と比較した従来型2回以上接種+2価ワクチン1回接種の相対的な発症予防効果(最終の従来型接種から2-3ヶ月→8ヶ月以上)は18-49歳30%→56%、50-64歳31%→48%、65歳以上28%→43%。 https://t…
RT @SukunaBikona7: 従来型2回以上接種と比較した従来型2回以上接種+2価ワクチン1回接種の相対的な発症予防効果(最終の従来型接種から2-3ヶ月→8ヶ月以上)は18-49歳30%→56%、50-64歳31%→48%、65歳以上28%→43%。 https://t…
RT @SukunaBikona7: 従来型2回以上接種と比較した従来型2回以上接種+2価ワクチン1回接種の相対的な発症予防効果(最終の従来型接種から2-3ヶ月→8ヶ月以上)は18-49歳30%→56%、50-64歳31%→48%、65歳以上28%→43%。 https://t…
RT @ENirenberg: MMWR is here: https://t.co/gryGnRiMg2
従来型2回以上接種と比較した従来型2回以上接種+2価ワクチン1回接種の相対的な発症予防効果(最終の従来型接種から2-3ヶ月→8ヶ月以上)は18-49歳30%→56%、50-64歳31%→48%、65歳以上28%→43%。 https://t.co/AgaNCg3tH2 2価ワクチン接種により発症予防効果のある程度の改善を認めたと。→
RT @MartyMakary: CDC just released its bivalent vax study-says effectiveness "should be interpreted with caution because unvaccinated perso…
@DocJeffD Subject to at least six limitations 👇
RT @MartyMakary: CDC just released its bivalent vax study-says effectiveness "should be interpreted with caution because unvaccinated perso…
RT @MartyMakary: CDC just released its bivalent vax study-says effectiveness "should be interpreted with caution because unvaccinated perso…
RT @MartyMakary: CDC just released its bivalent vax study-says effectiveness "should be interpreted with caution because unvaccinated perso…
RT @bhrenton: New today: First efficacy estimates against symptomatic COVID-19 in bivalent boosted people: - Bivalent boosters increased p…
RT @MartyMakary: CDC just released its bivalent vax study-says effectiveness "should be interpreted with caution because unvaccinated perso…
RT @DoctorTro: The media arm of Pfizer is advertising another retrospective review https://t.co/HeSlZQcnfS
RT @MartyMakary: CDC just released its bivalent vax study-says effectiveness "should be interpreted with caution because unvaccinated perso…
RT @AAPSonline: Receiving more doses does not seem to add much to vaccine efficacy as far as prevention of infection. Not to mention there…
RT @zin_zah: In this study of vaccine effectiveness of ... mRNA booster formulations, ... bivalent boosters provided significant additional…
New CDC MMWR on bivalent booster effectiveness can only add so much given its case-control nature & vulnerability to confounders (like if vaccinated ppl are more likely to test or less likely to have had recent infections): https://t.co/CnO20NZMx6 But
RT @AAPSonline: Receiving more doses does not seem to add much to vaccine efficacy as far as prevention of infection. Not to mention there…
Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 @cdcmmwr https://t.co/WQKrwp9Jqr
RT @MartyMakary: CDC just released its bivalent vax study-says effectiveness "should be interpreted with caution because unvaccinated perso…
The 1st effectiveness study of the new bivalent COVID vaccines finds they provide substantially more protection against Omicron-family variants than did the old boosters. Still time for you to get boosted (at nearly any pharmacy) before the holidays! https
RT @AAPSonline: Receiving more doses does not seem to add much to vaccine efficacy as far as prevention of infection. Not to mention there…
MMWR is here: https://t.co/gryGnRiMg2
RT @mahesh_shenai: @VPrasadMDMPH https://t.co/DwQr82zW0B And now, even the new MMWR study demonstrates that the bivalent booster are margi…
@VPrasadMDMPH https://t.co/DwQr82zW0B And now, even the new MMWR study demonstrates that the bivalent booster are marginally effective. But they are still pushing it as ultimate protection.
RT @Alexander_Tin: New in @CDCMMWR: our first look at effectiveness of updated bivalent boosters relative to 2 monovalent shots against s…
RT @AAPSonline: Receiving more doses does not seem to add much to vaccine efficacy as far as prevention of infection. Not to mention there…
RT @AAPSonline: Receiving more doses does not seem to add much to vaccine efficacy as far as prevention of infection. Not to mention there…
RT @photon_queen: 🎯
RT @AAPSonline: Receiving more doses does not seem to add much to vaccine efficacy as far as prevention of infection. Not to mention there…
Receiving more doses does not seem to add much to vaccine efficacy as far as prevention of infection. Not to mention there is some hint of depletion of VE with more than 2 shots. https://t.co/TFOJ4wXVgV https://t.co/eGemedpqUF
RT @bhrenton: New today: First efficacy estimates against symptomatic COVID-19 in bivalent boosted people: - Bivalent boosters increased p…
RT @mahesh_shenai: https://t.co/mVcJrbKQzQ Quick takes from new MMWR study on bivalent efficacy (after a monovalent series): 1. Modest <…
RT @MartyMakary: CDC just released its bivalent vax study-says effectiveness "should be interpreted with caution because unvaccinated perso…
🎯
New observational data on vaccine effectiveness against symptomatic case of #COVID19 for bivalent booster vaccines. https://t.co/eIimcUy9rr
RT @MartyMakary: CDC just released its bivalent vax study-says effectiveness "should be interpreted with caution because unvaccinated perso…
RT @MartyMakary: CDC just released its bivalent vax study-says effectiveness "should be interpreted with caution because unvaccinated perso…
RT @MartyMakary: CDC just released its bivalent vax study-says effectiveness "should be interpreted with caution because unvaccinated perso…
RT @zin_zah: In this study of vaccine effectiveness of ... mRNA booster formulations, ... bivalent boosters provided significant additional…
RT @zin_zah: Due to waning immunity of monovalent doses, the benefit of the bivalent booster increased with time since receipt of the most…
RT @MartyMakary: CDC just released its bivalent vax study-says effectiveness "should be interpreted with caution because unvaccinated perso…
RT @MartyMakary: CDC just released its bivalent vax study-says effectiveness "should be interpreted with caution because unvaccinated perso…
RT @Alexander_Tin: New in @CDCMMWR: our first look at effectiveness of updated bivalent boosters relative to 2 monovalent shots against s…
RT @MartyMakary: CDC just released its bivalent vax study-says effectiveness "should be interpreted with caution because unvaccinated perso…
RT @MartyMakary: CDC just released its bivalent vax study-says effectiveness "should be interpreted with caution because unvaccinated perso…